Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPI-based triple therapy with half-dose clarithromycin for clarithromycin-sensitive Helicobacter pylori eradication
KCT0009996Phase 4Recruiting
- Sponsor
- Chonnam National University Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of clarithromycin in Helicobacter pylori infection, gastric ulcer, duodenal ulcer, gastric cancer (GC), gastric adenocarcinoma, sponsored by Chonnam National University Hospital. Started Sep 2024; status: recruiting.
02
Drugs
clarithromycin
03
Conditions
Helicobacter pylori infectiongastric ulcerduodenal ulcergastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on KCT0009996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009996.